Small Scale Bioreactors Market to Surpass USD 2.9 Billion by 2033

Small Scale Bioreactors Market Reaches USD 2.1 Bn in 2026, Driven by Rising Biopharmaceutical R&D and Cell Culture Applications

Single-Use Bioreactors and Process Automation to Drive Small Scale Bioreactors Market to USD 2.9 Billion by 2033 at 9.2% CAGR – Coherent Market Insights

The Small Scale Bioreactors Market, estimated at USD 2.1 Bn in 2026, is expected to exhibit a CAGR of 9.2 % and reach USD 2.9 Bn by 2033.

Global Small Scale Bioreactors Market, by  Product Type [Reusable Bioreactors ( Stainless Steel Bioreactors, Glass Bioreactors) Single-use Bioreactor] By Capacity (5 ML-100 ML,100 ML-250ML, 250ML-500ML, 500ML-1L, 1L-3L, 3L-5L), By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Research Organizations), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ USD 2.1 Bn in 2026 and is expected to exhibit a CAGR of 9.2% during the forecast period (2026-2033).

Increasing marketing activities for products by the market players is expected to drive the growth of the global small scale bioreactors market over the forecast period. For instance, on April 1, 2021, Getinge announced to become the supplier of Applikon bioreactors in France, Sweden, and Germany. Getinge is a global medical technology company which had acquired Applikon, a manufacturer of bioreactors, on January 1, 2020.

Key players are focused on research and development activities on small scale bioreactors, which is expected to drive the growth of the global small scale bioreactors market over the forecast period. For instance, on April 20, 2018, Sartorius Stedim Biotech which is pharmaceutical industry’s leading worldwide partner introduced Mini Microcarrier Bioreactor for Culturing Adherent Cells. This device will be cost effective and vaccine development will possible with cell cultures by using scalable processing. The capacity of this device is 100ML- 250ML.This mini vessel is tested by bioprocess experts at Aston University and university college of London where it came about as the gadget is empowered for development to intersection of vero cells  on cytodex micro carrier’s surface.

Browse 31 Market Data Tables and 46 Figures spread through 196 Pages and in-depth TOC on Global Small Scale Bioreactors Market, by  Product Type [Reusable Bioreactors (Stainless Steel Bioreactors, Glass Bioreactors), Single-use Bioreactor],  By Capacity (5 ML-100ML, 100ML-250ML, 250ML-500ML, 500ML-1L, 1L-3L, 3L-5L), By End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, Research Organizations ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global small scale bioreactors market, click the link below:

https://www.coherentmarketinsights.com/market-insight/small-scale-bioreactors-market-4828

Increasing prevalence of diseases indicates the need of vaccine production which is expected to drive the growth of the global small scale bioreactors market over the forecast period. For instance, Medigene is working on the development of innovative immunotherapies such as T cell activity against solid cancers such as receptor-modified T cells (TCR‑Ts) or dendritic cell (DC) vaccines to treat cancer.  The first product candidates are in clinical development.

Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers. 

Key News

• In July 2026, NTx Bio, biomanufacturing company introduced NTxscribe FLEX, a benchtop continuous-flow RNA production system designed for process development, translational research, and RNA therapeutic programs. Built on patented hollow fiber bioreactor architecture, the platform automates RNA production from DNA template through initial purification in hours. Its compact, customizable, single-operator format supports scalable RNA output, with RUO availability from summer 2026 and GMP capability expected in early 2027 for future clinical scale-up.
• In June 2026, Bioengineering, part of Morimatsu LifeSciences, concluded its global new product launch in Shanghai, introducing five core biomanufacturing products: Taberis Xpert, Taberis Prime, Taberis Parasmart, Ondalis, and Bagento. The portfolio supports laboratory research, pilot scale-up, and commercial production. It also advances integrated workflows, data-driven bioprocessing, and interconnected manufacturing, supported by the upgraded BIOSCADA II intelligent process control platform for improved efficiency, transparency, scalability, and sustainability worldwide across operations.
• In May 2026, Thermo Fisher Scientific introduced the Gibco CTS DynaXS Single Use Bioreactor, a purpose-built, stirred-tank platform for scalable cell therapy manufacturing. The system supports cell expansion from small process-development batches to larger cGMP manufacturing runs, while improving process control, flexibility, regulatory readiness, and automation. The launch highlights rising innovation in small-scale bioreactors as developers move from static culture systems toward scalable, closed manufacturing platforms for advanced therapies globally.

(Source: Thermo Fisher Scientific)

Key Takeaways of the Small Scale Bioreactors Market

• The global small scale bioreactors market is expected to exhibit a CAGR of 9.2% over the forecast period (2026-2033), owing to growth in potential markets, especially in Europe, while North America region accounted for the major market share for year 2026.
• Key players operating in the market are focusing on investing in bioreactors and manufacturing facilities containing bioreactors for the development of drugs, vaccines, and cell culture based products, which is expected to drive the growth of small scale bioreactors. For instance, in July 2021, Cytiva and Pall Corporation, both Danaher Corporation subsidiaries, announced plans to invest US$ 1.5 billion to expand manufacturing capacity for their life science customers across 13 sites globally. The companies will invest in chromatography resins, cell culture media, and single-use bioreactor technologies.
• Some of the major players operating in the global small scale bioreactors market include Merck KGaA, Danaher Corporation, Getinge AB, Sartorius AG, Thermo Fisher Scientific Inc., Lonza Group, Eppendorf AG, Miltenyi Biotec, Solaris Biotechnology Srl, Infors AG,Biosan, MicroDigital Co. Ltd., 2mag AG, MDX Biotechnik International GmbH, Esco Lifesciences Group, HiTec Zang GmbH, Hanil Scientific Inc., Adolf Kühner AG, Ori Biotech, Aglaris and AdvaBio.